Recent blog posts
Amylyx Reveals Key Findings from Worldwide Stage 3 PHOENIX Study on AMX0035 for ALS Treatment
Latest Hotspot
3 min read
Amylyx Reveals Key Findings from Worldwide Stage 3 PHOENIX Study on AMX0035 for ALS Treatment
12 March 2024
Amylyx Pharmaceuticals released initial results from their Phase 3 PHOENIX study, a 48-week global, randomized, double-blind, placebo-controlled trial, assessing AMX0035 in ALS patients.
Read →
VISEN Announces China's Approval to Submit Lonapegsomatropin Biologic License
Latest Hotspot
3 min read
VISEN Announces China's Approval to Submit Lonapegsomatropin Biologic License
12 March 2024
VISEN Reveals China's Endorsement of Submission for the Biologic Drug License Concerning Lonapegsomatropin.
Read →
Akari Therapeutics Merges with Peak Bio to Expand ADC Portfolio
Latest Hotspot
3 min read
Akari Therapeutics Merges with Peak Bio to Expand ADC Portfolio
7 March 2024
Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.
Read →
1.0 mg Semaglutide Reduces Kidney Disease Events by 24% in Type 2 Diabetics with Chronic Conditions
Latest Hotspot
3 min read
1.0 mg Semaglutide Reduces Kidney Disease Events by 24% in Type 2 Diabetics with Chronic Conditions
7 March 2024
Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.
Read →
Weekly Islatravir-Lenacapavir Combo Maintains Viral Control in Phase 2 Trial
Latest Hotspot
3 min read
Weekly Islatravir-Lenacapavir Combo Maintains Viral Control in Phase 2 Trial
7 March 2024
Gilead Sciences and Merck unveil preliminary results from stage two trial revealing that a weekly oral blend of Islatravir and Lenacapavir successfully sustained control over viral levels up to the 24-week mark.
Read →
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
Latest Hotspot
4 min read
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
7 March 2024
Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.
Read →
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
Latest Hotspot
3 min read
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
7 March 2024
Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.
Read →
Pfizer's Clinical Advancements with Drug PF-08046052 Reported by LAVA
Latest Hotspot
3 min read
Pfizer's Clinical Advancements with Drug PF-08046052 Reported by LAVA
7 March 2024
LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.
Read →
First Patient Treated in IPH6501 Trial for Relapsed/Refractory B-Cell NHL
Latest Hotspot
3 min read
First Patient Treated in IPH6501 Trial for Relapsed/Refractory B-Cell NHL
7 March 2024
Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.
Read →
Promising Early Results for BI-1206 in Chinese Non-Hodgkin's Lymphoma Study by CASI Pharma
Latest Hotspot
3 min read
Promising Early Results for BI-1206 in Chinese Non-Hodgkin's Lymphoma Study by CASI Pharma
7 March 2024
CASI Pharma Announces Encouraging Early Results for BI-1206 in Managing Persistent Forms of Non-Hodgkin’s Lymphoma in Chinese Study.
Read →
Nektar Launches Phase 2b Trial for Severe Alopecia Areata Treatment
Latest Hotspot
3 min read
Nektar Launches Phase 2b Trial for Severe Alopecia Areata Treatment
7 March 2024
Nektar Therapeutics has launched a Phase 2b trial to assess Rezpegaldesleukin in individuals with severe forms of Alopecia Areata.
Read →
Ankrya Therapeutics Begins Human Trials for ANK-101, a New Cancer Immunotherapy
Latest Hotspot
3 min read
Ankrya Therapeutics Begins Human Trials for ANK-101, a New Cancer Immunotherapy
7 March 2024
Ankyra Therapeutics has commenced dosing in its initial human trial phase, assessing the effectiveness of ANK-101, a novel anchored immunotherapy, targeting a range of solid cancers.
Read →